Skip to main content
NADFaq.com

Benefit

Inflammation & Inflammaging

CD38, SIRT1/SIRT6, and chronic low-grade inflammation.

Emerging human evidence

Chronic age-associated inflammation ("inflammaging") coincides with CD38-driven NAD+ consumption in inflamed tissues and reduced sirtuin deacetylase activity on NF-κB and p65. SIRT1 and SIRT6 suppress pro-inflammatory transcription in preclinical models, and NAD+ restoration attenuates senescence-associated secretory phenotype output. Human trials show modest effects on circulating inflammatory markers and remain small in scale.

Key studies

  1. Cell Metabolism · 2016 · PMID 27304511

    CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism

    Camacho-Pereira J, et al.

    Read summary

  2. Cell · 2009 · PMID 19410543

    SIRT6 links histone H3 lysine 9 deacetylation to NF-κB-dependent gene expression and organismal life span

    Kawahara TLA, et al.

  3. Nature Communications · 2018 · PMID 29599478

    Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults

    Martens CR, et al.

    Read summary

Editorial note

NADFaq grades evidence on a 4-tier scale based on human trial quality, sample size, reproducibility, and mechanistic plausibility. This is a conservative framework — many published benefits of NAD+ precursors rest on preclinical (rodent or cell) work that has not yet translated to humans.

How we grade evidence